[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353415-105":59,"doc-detail-353415-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","exceptional-treatment-responses-and-molecular-markers-among-103-colorectal-cancer-cell-lines","Exceptional treatment responses and molecular markers among 103 colorectal cancer cell lines","","Patients with colorectal cancer have few molecularly guided treatment options. Cancers with exceptional treatment response offer valuable models to uncover molecular response mechanisms and identify predictive biomarkers for treatment selection, though the rarity of such events limits clinical evaluation. This study used integrated high-throughput drug sensitivity testing (n = 620 drugs) and molecular analyses of 103 colorectal cancer cell lines to establish an in vitro basis for exceptional responses and their molecular markers, including model-based prediction.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exceptional-treatment-responses-and-molecular-markers-among-103-colorectal-cancer-cell-lines/353415/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exceptional-treatment-responses-and-molecular-markers-among-103-colorectal-cancer-cell-lines/353415.png","ImageObject",300,407,{"name":92,"@type":93},"anakgang17","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the goal of studying exceptional treatment responses in colorectal cancer cell lines?","Question",{"text":113,"@type":114},"The study aims to uncover molecular response mechanisms and identify predictive biomarkers that can guide treatment selection despite limited molecularly guided options for colorectal cancer patients.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were exceptional responses identified in the 103 cell line-drug panel?",{"text":118,"@type":114},"Exceptional responses were scored using a two-way outlier detection approach applied to integrated high-throughput drug sensitivity testing across 103 colorectal cancer cell lines and 620 drugs.",{"name":120,"@type":111,"acceptedAnswer":121},"What evidence supports molecular marker suppression after treatment?",{"text":122,"@type":114},"Experimental validation confirmed treatment-induced marker suppression in seven of eight selected cell line-drug pairs, including target engagement of kinase inhibitors and downregulation of markers linked to extended response mechanisms.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},353415,1790494073,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Sveen et al. Molecular Biomedicine (2026) 7:150 Molecular Biomedicine  \n[https://doi.org/10.1186/s43556-026-00551-z](https://doi.org/10.1186/s43556-026-00551-z)  \n RESEARCH Open Access  \nExceptional treatment responses and  \nmolecular markers among 103 colorectal cancer cell lines  \nAnita Sveen1,2* , Jakob M. Stenersen 1,2, Theophilus Quachie Asenso3, Solveig K. Klokkerud 1, Christian Kranjec 1, Ina A. Eilertsen 1, Bjarne Johannessen1, Edward Leithe 1, Kushtrim Kryeziu 1, Manuela Zucknick3,4 and Ragnhild A. Lothe 1,2  \nAbstract  \nPatients with colorectal cancer have few molecularly guided treatment options. Cancers with exceptional treatment response are valuable models for discovery of molecular response mechanisms and might reveal new predictive biomarkers to guide treatment selection. However, the rarity of events is a clinical challenge. We performed integrated high-throughput drug sensitivity testing (n = 620 drugs) and molecular analyses of 103 colorectal cancer cell lines to build an in vitro foundation for exceptional treatment responses and their molecular markers. Exceptional responses were scored by a two-way outlier detection approach and were identified in 67 unique cell line-drug pairs (0 . 13% of all pairs tested) . This involved 35 cell lines (34 . 0%) and 49 drugs (7 . 9%) representing standard, experimental, and non-oncology drugs of diverse classes. Plausible response mechanisms on the gene, protein, and/or pathway expression levels were identified at baseline in 89. 6% of the 67 pairs. Experimental validation confirmed treatmentinduced marker suppression in seven of eight selected pairs, including target engagement of kinase inhibitors and downregulation of markers of extended response mechanisms. Recurrent exceptional sensitivity to the same drug in different cell lines involved functionally convergent molecular mechanisms, but rarely precisely the same marker. Most exceptional sensitivities (77 . 8%) could be predicted with multivariable transcriptomic models. In conclusion, this study provides in vitro support for biomarker-guided prescreening to potentially obtain exceptional treatment response to diverse drugs and therapeutic targets in colorectal cancer. Most exceptional responses have a clear molecular underpinning. The study also provides a large and openly available pharmaco-transcriptomics resource for colorectal cancer cell lines.  \nKeywords Colorectal cancer, Cell lines, Drug sensitivity testing, Exceptional treatment response, Prediction biomarkers, Transcriptomics  \n*Correspondence:  \nAnita Sveen  \n[anita.sveen@medisin.uio. no](anita.sveen@medisin.uio. no)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nSveen et al. Molecular Biomedicine (2026) 7:150  \nIntroduction  \nCancers with exceptional response to systemic therapy are particularly attractive models for investigation of molecular response mechanisms [1]. Extreme treatment responses are expected to have a strong molecular underpinning and might reveal new predi","cbCaifYExC8gFQX5","https://ap.wps.com/l/cbCaifYExC8gFQX5","pdf",2891506,18,"English","# Abstract\n## Introduction\n### Exceptional treatment responses as models\n### Evidence from exceptional responders initiatives","[{\"question\":\"What is the goal of studying exceptional treatment responses in colorectal cancer cell lines?\",\"answer\":\"The study aims to uncover molecular response mechanisms and identify predictive biomarkers that can guide treatment selection despite limited molecularly guided options for colorectal cancer patients.\"},{\"question\":\"How were exceptional responses identified in the 103 cell line-drug panel?\",\"answer\":\"Exceptional responses were scored using a two-way outlier detection approach applied to integrated high-throughput drug sensitivity testing across 103 colorectal cancer cell lines and 620 drugs.\"},{\"question\":\"What evidence supports molecular marker suppression after treatment?\",\"answer\":\"Experimental validation confirmed treatment-induced marker suppression in seven of eight selected cell line-drug pairs, including target engagement of kinase inhibitors and downregulation of markers linked to extended response mechanisms.\"}]","Exceptional treatment responses and molecular markers among 103 colorectal cancer cell lines | PDF",1790105196,45,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/855d27b4d173e4099e721e5a92bf182a.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0311455541952462b22e24b8fac4d44c.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8b3a34719ad7ea0fd897c927f4153ed.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7021108db370b77afa1e096d0c07988b.webp",980,1301]